Journal article
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report.
-
Dingemans AC
Department of Pulmonary Diseases, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Pulmonary Diseases, Erasmus Medical Centre, Rotterdam, The Netherlands; GROW - School for oncology and developmental biology, University Maastricht, The Netherlands. Electronic address: a.dingemans@erasmusmc.nl.
-
Hendriks LEL
Department of Pulmonary Diseases, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - School for oncology and developmental biology, University Maastricht, The Netherlands.
-
Berghmans T
Department of Intensive Care and Oncological Emergencies & Thoracic Oncology, Brussels, Belgium; Jules Bordet Institute, Brussels Free University, Brussels, Belgium.
-
Levy A
Department of Radiation Oncology, Gustave Roussy, Thoracic Oncology Institute (IOT), Villejuif, France; Paris Saclay University, Saint-Aubin, France.
-
Hasan B
European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
-
Faivre-Finn C
The Christie NHS Foundation Trust, Manchester, United Kingdom; University of Manchester, Manchester, United Kingdom.
-
Giaj-Levra M
Respiratory Oncology Unit, Department of Thoracic and Vascular disease, Grenoble Alpes University Hospital, Grenoble, France.
-
Giaj-Levra N
Department of Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy; Department of Oncology, University of Turin, Torino, Italy.
-
Girard N
Department of Medical Oncology, Institute Curie, Thorax Institute Curie Montsouris, Paris, France.
-
Greillier L
Multidisciplinary Oncology and Therapeutic Innovations, Marseille University Hospital (APHM), Marseille, France; Aix Marseille University, Marseille, France.
-
Lantuéjoul S
Department of Biopathology, Centre Léon Bérard UNICANCER, Lyon, France; Université Grenoble Alpes, INSERM U1209/CNRS 5309 Institute for Advanced Biosciences, Grenoble France.
-
Edwards J
Department of Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield, United Kingdom.
-
O'Brien M
Department of Medical Oncology, Royal Marsden Hospital, London, United Kingdom.
-
Reck M
Department of Thoracic Oncology, Airway Research Center North, German Center of Lung Diseases, Lung Clinic, Grosshansdorf, Germany.
-
Smit EF
dept of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
-
Van Schil P
Department of Thoracic and Vascular Surgery, Antwerp University Hospital, B-2650 Edegem (Antwerp), Belgium.
-
Postmus PE
Department of pulmonology, Leiden University Medical Center, Leiden, The Netherlands.
-
Ramella S
Radiation Oncology, Campus Bio-Medico University, Rome, Italy.
-
Lievens Y
Radiation Oncology Department, Ghent University Hospital Ghent, Belgium; Ghent University, Ghent, Belgium.
-
Gaga M
Seventh Respiratory Medicine Dept, Athens Chest Hospital Sotiria, Athens, Greece; European Respiratory Society, Lausanne, Switzerland.
-
Peled N
The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Cancer Center, Beer-Sheva, Israel; Ben Gurion University, Beer-Sheva, Israel.
-
Scagliotti GV
Oncology Department, University of Turin, AOU San Luigi, Orbassano (TO), Italy.
-
Senan S
Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, The Netherlands.
-
Paz-Ares L
Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
-
Guckenberger M
Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland.
-
McDonald F
Department of Radiotherapy, Royal Marsden Hospital, London, United Kingdom.
-
Ekman S
Thoracic Oncology Center, Karolinska University Hospital/ Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
-
Cufer T
University Clinic Golnik, Ljubljana, Slovenia; Medical Faculty, University of Ljubljana, Slovenia.
-
Gietema H
GROW - School for oncology and developmental biology, University Maastricht, The Netherlands; Department of Radiology, Maastricht University Medical Center+, Maastricht, The Netherlands.
-
Infante M
Thoracic Surgery Dept. University and Hospital Trust - Ospedale Borgo Trento, Verona, Italy.
-
Dziadziuszko R
Department of Oncology and Radiotherapy, Medical University of Gdansk, 80-211 Gdansk, Poland.
-
Peters S
Oncology Department, University Hospital (CHUV), 1011 Lausanne, Switzerland.
-
Porta RR
Department of Thoracic Surgery, Mútua Terrassa University Hospital, University of Barcelona, Terrassa, Terrassa, Barcelona, Spain; Network of Centers for Biomedical Research on Respiratory Diseases (CIBERES) Lung Cancer Group, Terrassa, Barcelona, Spain.
-
Vansteenkiste J
Respiratory Oncology Unit, Department of Respiratory Diseases KU Leuven, Leuven, Belgium.
-
Dooms C
Respiratory Oncology Unit, Department of Respiratory Diseases KU Leuven, Leuven, Belgium.
-
de Ruysscher D
GROW - School for oncology and developmental biology, University Maastricht, The Netherlands; Department of Radiation Oncology, MAASTRO Clinic, Maastricht, The Netherlands.
-
Besse B
Paris Saclay University, Saint-Aubin, France; Department of cancer medicine, Gustave Roussy, Villejuif, France.
-
Novello S
Oncology Department, University of Turin, AOU San Luigi, Orbassano (TO), Italy.
Show more…
Published in:
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. - 2019
English
INTRODUCTION
Improved outcome has been shown in patients with synchronous oligometastatic (sOM) NSCLC when treated with radical intent. As a uniform definition of sOM NSCLC is lacking, we developed a definition and diagnostic criteria by a consensus process.
METHODS
A pan-European multidisciplinary consensus group was established. Consensus questions were built on the basis of current controversies, and definitions were extracted from a survey, cases and a systematic review. This statement was formulated during a consensus meeting.
RESULTS
It was determined that definition of sOM NSCLC is relevant when a radical treatment that may modify the disease course (leading to long-term disease control) is technically feasible for all tumor sites with acceptable toxicity. On the basis of the review, a maximum of five metastases and three organs was proposed. Mediastinal lymph node involvement was not counted as a metastatic site. Fludeoxyglucose F 18 positron emission tomography-computed tomography and brain imaging were considered mandatory. A dedicated liver magnetic resonance imaging scan was advised for a solitary liver metastasis, and thoracoscopy and biopsies of distant ipsilateral pleural sites were recommended for a solitary pleural metastasis. For mediastinal staging, fludeoxyglucose F 18 positron emission tomography-computed tomography was deemed the minimum requirement, with pathological confirmation recommended if this influences the treatment strategy. Biopsy of a solitary metastatic location was mandated unless the multidisciplinary team is of the opinion that the risks outweigh the benefits.
CONCLUSION
A multidisciplinary consensus statement on the definition and staging of sOM NSCLC has been formulated. This statement will help to standardize inclusion criteria in future clinical trials.
-
Language
-
-
Open access status
-
bronze
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/3881
Statistics
Document views: 23
File downloads: